Ascendiant Capital initiated coverage on GRI Bio, Inc. (NASDAQ:GRI) with a Buy rating and a 12-month price target of $12. The firm's focus on the company stems from its work in the clinical-stage biopharmaceutical sector, particularly on diseases linked to dysregulated immune responses.
GRI Bio's research is centered around the concept that immune responses can be regulated by targeting NKT (Natural Killer T) cells, offering potential treatments for a variety of acute and chronic conditions. The company's primary candidate, GRI-0621, is under development for the treatment of Idiopathic Pulmonary Fibrosis (IPF). Unlike treatments that address symptoms, GRI-0621 is designed to inhibit the activity of iNKT cells, thereby resetting the dysfunctional immune response believed to drive the disease.
In December 2023, GRI Bio began enrolling patients for the Phase 2a Trial of GRI-0621. This multicenter, multinational, randomized, placebo-controlled trial aims to involve approximately 36 IPF patients over a twelve-week period. The completion of the trial is anticipated to take around one year.
The initiation of coverage by Ascendiant Capital marks a significant moment for GRI Bio as it navigates the clinical trial process for its leading drug candidate. The Buy rating and price target reflect the firm's confidence in the company's approach to treating diseases with immune response irregularities.
GRI Bio has secured a patent in Japan for its Natural Killer T (NKT) cell modulators, broadening its intellectual property portfolio in the world's third-largest pharmaceutical market. Concurrently, Australian regulatory authorities have granted the company permission to commence a Phase 2a biomarker study for its lead program, GRI-0621, which is aimed at treating Idiopathic Pulmonary Fibrosis. GRI Bio has also been dealing with a notification from the Nasdaq Stock Market regarding non-compliance with the minimum bid price requirement, and is considering various options to regain compliance within the granted 180-day period.
GRI Bio has expanded its at-the-market offering program, allowing for the issuance of an aggregate of $2,644,609 worth of the company's common stock. The company has also announced a public offering of over 2 million shares of common stock and Series C warrants, expected to generate about $4 million. In addition, GRI Bio initiated a 1-for-13 reverse stock split, reducing the total outstanding shares from approximately 6.6 million to about 508,091 shares.
A recent shareholder meeting saw the election of a director, approval of common stock issuances, and an equity plan amendment. The company also regained compliance with Nasdaq's listing standards, canceling a previously scheduled hearing with the Nasdaq Hearings Panel.
InvestingPro Insights
While Ascendiant Capital's initiation of coverage on GRI Bio with a Buy rating and a $12 price target reflects optimism about the company's potential, it's crucial to consider current financial metrics and market performance. According to InvestingPro data, GRI Bio's market capitalization stands at just $1.01 million, with the stock trading at $0.35 as of the previous close. This represents a significant gap from the analyst's target price.
InvestingPro Tips highlight that GRI Bio is quickly burning through cash and is not profitable over the last twelve months. These factors are particularly relevant for a clinical-stage biopharmaceutical company like GRI Bio, as they underscore the financial challenges often faced during the drug development process.
The company's stock performance has been notably weak, with InvestingPro data showing a 99.76% decline over the past year and a 78.88% drop in the last three months. This trend aligns with the InvestingPro Tip indicating that the stock has fared poorly over the last month.
For investors considering GRI Bio, it's worth noting that InvestingPro offers 13 additional tips that could provide further insights into the company's financial health and market position. These additional tips could be particularly valuable in assessing the risks and potential of investing in a clinical-stage biopharmaceutical company like GRI Bio.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.